Quest Diagnostics Cash Flow from Operating Activities 2010-2025 | DGX

Quest Diagnostics annual/quarterly cash flow from operating activities history and growth rate from 2010 to 2025. Cash flow from operating activities can be defined as a company's cash flows from operations.
  • Quest Diagnostics cash flow from operating activities for the quarter ending March 31, 2025 was $1.334B, a 4.87% increase year-over-year.
  • Quest Diagnostics cash flow from operating activities for the twelve months ending March 31, 2025 was $2.872B, a 8.42% increase year-over-year.
  • Quest Diagnostics annual cash flow from operating activities for 2024 was $1.334B, a 4.87% increase from 2023.
  • Quest Diagnostics annual cash flow from operating activities for 2023 was $1.272B, a 25.96% decline from 2022.
  • Quest Diagnostics annual cash flow from operating activities for 2022 was $1.718B, a 23.06% decline from 2021.
Quest Diagnostics Annual Cash Flow Ops
(Millions of US $)
2024 $1,334
2023 $1,272
2022 $1,718
2021 $2,233
2020 $2,005
2019 $1,243
2018 $1,200
2017 $1,175
2016 $1,116
2015 $821
2014 $944
2013 $652
2012 $1,187
2011 $895
2010 $1,118
2009 $997
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $18.282B $9.872B
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
Stock Name Country Market Cap PE Ratio
DaVita (DVA) United States $11.202B 14.29
Encompass Health (EHC) United States $10.408B 23.33
Chemed (CHE) United States $8.501B 27.28
Option Care Health (OPCH) United States $5.259B 25.21
Elanco Animal Health (ELAN) United States $4.190B 9.27
RadNet (RDNT) United States $3.686B 79.02
Amedisys (AMED) United States $3.011B 21.29
LifeStance Health (LFST) United States $2.576B 0.00
Addus HomeCare (ADUS) United States $1.840B 21.32
Astrana Health (ASTH) United States $1.573B 35.26
U.S Physical Therapy (USPH) United States $1.025B 26.14
Pennant (PNTG) United States $0.907B 36.29
Aveanna Healthcare Holdings (AVAH) United States $0.886B 0.00
Atai Life Sciences (ATAI) Germany $0.294B 0.00
Daxor (DXR) United States $0.036B 0.00
Ontrak (OTRK) United States $0.006B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.004B 0.00
Psychemedics (PMD) United States $0.000B 0.00